Free Republic

On the latest episode of “The Jimmy Dore Show,” comedian and political commentator Jimmy Dore highlighted the similarities between Pfizer’s expensive new antiviral drug for COVID and ivermectin, a generic drug used to treat the virus.“I’ve never seen the propaganda machine so hard at work as it’s been against ivermectin,” said Dore. “Ivermectin won a Nobel Prize for human medicine in 2015, but the media really has everyone believing it’s for horses.” Dore suggested the motivation behind the propaganda is profits.Dore played a video of John Campbell, Ph.D., explaining how Pfizer’s antiviral and ivermectin treat COVID in “the exact same...

Weird that two are “snake oil” and the expensive one will get EUA {Emergency Use Authorization by the FDA}

Video showing that Pfizers new anti-viral drug is virtually the same as Ivermectin. And interestingly they have research that their version of ivermectin works against COVID but they have no research that the real ivermectin works. Of course the real Ivermectin costs 10 cents a pill outside the US.

An experimental pill to treat Covid developed by the US company Pfizer cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest. The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease. . . . . Interim data from trials of the treatment in 1,219 high-risk patients who had recently been infected with Covid found that 0.8% of those given Paxlovid were hospitalised compared with 7% of patients who were given a placebo or dummy pill. They were treated within three days of...

Anthony Fauci, the government's top infectious diseases expert, on Friday called new trial results for a Merck pill to treat COVID-19 "impressive," as experts say the treatment could be a key tool in the pandemic fight. "The data are impressive," Fauci said at a White House press briefing, noting he was briefed by the company on its results on Thursday night. Merck said in a press release that the trial found that its drug cut the risk of hospitalization or death by 50 percent. Eight trial participants who received a placebo died, compared to zero who received the drug from...

At the start of the pandemic, researchers began testing existing antivirals in people hospitalized with severe Covid-19. But many of those trials failed to show any benefit from the antivirals. In hindsight, the choice to work in hospitals was a mistake. Scientists now know that the best time to try to block the coronavirus is in the first few days of the disease, when the virus is replicating rapidly and the immune system has not yet mounted a defense. In a trial of hospitalized patients, however, molnupiravir seemed to have no effect on the disease. In April, the companies announced...

@MaajidNawaz The patent for ivermectin had expired, so Pfizer needed to redesign it in order to sell it under a new patent. Pfizer is laughing at us all, and MSM went along like suckers. The public was deceived for profit once again. As per Dr @PierreKory “there are 44 published, peer-reviewed studies of IVM in COVID - 11 Double blind RCT's, 12 open RCT's, 1 single blind RCT, 2 PSM OCT's- nearly all showing MASSIVE benefits..+ >30 non-RCT's show the same. NIH could give a weak/cautious rec.. but wont. Insane” “Ivermectin fights 21 viruses, incl. SARS-CoV-2, the cause of Covid-19....

Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus. The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG , have been racing to develop an easy-to-administer antiviral pill for COVID-19. The mid-to-late-stage study will test Pfizer's drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection. In the trial, PF-07321332, designed...

What this screenshot demonstrates is that Pfizer’s new twice-daily pill for Covid utilizes an unknown protease inhibitor, while including a snip from this study showing that Ivermectin also acts as a protease inhibitor. Just another data point in favor of Ivermectin. NIH Study — Ivermectin is ‘highly effective’ against key proteins of SARS-CoV-2 pathogenesis